Risk factors and a prognostic model for postsplenectomy survival in myelofibrosis
Sign Up to like & getrecommendations! Published in 2017 at "American Journal of Hematology"
DOI: 10.1002/ajh.24881
Abstract: Palliative treatment in myelofibrosis (MF) includes transfusion support, JAK2 inhibitors, involved field radiotherapy and splenectomy. To assist in selecting patients who are likely to benefit from splenectomy, we looked into risk factors for postsplenectomy survival,… read more here.
Keywords: risk; myelofibrosis; risk factors; postsplenectomy survival ... See more keywords
The clinical dilemma of JAK inhibitor failure in myelofibrosis: Predictive characteristics and outcomes
Sign Up to like & getrecommendations! Published in 2022 at "Cancer"
DOI: 10.1002/cncr.34222
Abstract: Two Janus‐associated kinase inhibitors (JAKi) (initially ruxolitinib and, more recently, fedratinib) have been approved as treatment options for patients who have intermediate‐risk and high‐risk myelofibrosis (MF), with pivotal trials demonstrating improvements in spleen volume, disease… read more here.
Keywords: clinical dilemma; jaki; inhibitor; myelofibrosis ... See more keywords
Ruxolitinib in cytopenic myelofibrosis: Response, toxicity, drug discontinuation, and outcome
Sign Up to like & getrecommendations! Published in 2023 at "Cancer"
DOI: 10.1002/cncr.34722
Abstract: Patients with cytopenic myelofibrosis (MF) have more limited therapeutic options and poorer prognoses compared with patients with the myeloproliferative phenotype. read more here.
Keywords: myelofibrosis response; response toxicity; ruxolitinib cytopenic; cytopenic myelofibrosis ... See more keywords
Targeted molecular characterization shows differences between primary and secondary myelofibrosis
Sign Up to like & getrecommendations! Published in 2019 at "Genes"
DOI: 10.1002/gcc.22789
Abstract: In BCR‐ABL1‐negative myeloproliferative neoplasms, myelofibrosis (MF) is either primary (PMF) or secondary (SMF) to polycythemia vera or essential thrombocythemia. MF is characterized by an increased risk of transformation to acute myeloid leukemia (AML) and a… read more here.
Keywords: molecular characterization; targeted molecular; shows differences; differences primary ... See more keywords
Risk factors for progression to blast phase and outcome in 589 patients with myelofibrosis treated with ruxolitinib: Real‐world data
Sign Up to like & getrecommendations! Published in 2020 at "Hematological Oncology"
DOI: 10.1002/hon.2737
Abstract: The impact of ruxolitinib therapy on evolution to blast phase (BP) in patients with myelofibrosis (MF) is still uncertain. In 589 MF patients treated with ruxolitinib, we investigated incidence and risk factors for BP and… read more here.
Keywords: risk; blast phase; treated ruxolitinib; myelofibrosis ... See more keywords
Ruxolitinib combined with prednisone, thalidomide and danazol in patients with myelofibrosis: Results of a pilot study
Sign Up to like & getrecommendations! Published in 2022 at "Hematological Oncology"
DOI: 10.1002/hon.3026
Abstract: Ruxolitinib is a safe and effective therapy of myeloproliferative neoplasm‐associated (MPN) myelofibrosis. However, often there are dose reductions and/or therapy interruptions because of therapy‐related adverse events (AEs), especially anemia and thrombocytopenia. We previously reported combined… read more here.
Keywords: ruxolitinib; study group; danazol; group ... See more keywords
Infections associated with ruxolitinib: study in the French Pharmacovigilance database
Sign Up to like & getrecommendations! Published in 2018 at "Annals of Hematology"
DOI: 10.1007/s00277-018-3242-8
Abstract: Dear Editor, Ruxolitinib, an orally bioavailable potent and selective inhibitor of Janus kinases (JAKs) 1 and 2, has been approved in Europe for the treatment of myelofibrosis and polycythemia vera. Ruxolitinib improves disease-related constitutional symptoms,… read more here.
Keywords: ruxolitinib; french pharmacovigilance; pharmacovigilance database; myelofibrosis ... See more keywords
Association between myelofibrosis and risk of non-hematologic malignancies: a population-based retrospective cohort study
Sign Up to like & getrecommendations! Published in 2020 at "Annals of Hematology"
DOI: 10.1007/s00277-020-03973-z
Abstract: Controversy regarding the risk of non-hematologic malignancies in myelofibrosis patients still exists. We aimed to examine the association between myelofibrosis and non-hematologic malignancies. A cohort of 1,469,790 adults without a diagnosis of myelofibrosis was identified… read more here.
Keywords: non hematologic; myelofibrosis; hematologic malignancies; association ... See more keywords
Management of myelofibrosis after ruxolitinib failure
Sign Up to like & getrecommendations! Published in 2020 at "Annals of Hematology"
DOI: 10.1007/s00277-020-04002-9
Abstract: Myelofibrosis is a BCR-ABL1–negative myeloproliferative neoplasm characterized by anemia, progressive splenomegaly, extramedullary hematopoiesis, bone marrow fibrosis, constitutional symptoms, leukemic progression, and shortened survival. Constitutive activation of the Janus kinase/signal transducers and activators of transcription (JAK-STAT)… read more here.
Keywords: ruxolitinib failure; fedratinib; ruxolitinib; myelofibrosis ruxolitinib ... See more keywords
Ruxolitinib-based combinations in the treatment of myelofibrosis: worth looking forward to
Sign Up to like & getrecommendations! Published in 2020 at "Annals of Hematology"
DOI: 10.1007/s00277-020-04028-z
Abstract: Ruxolitinib is a targeted drug to treat myelofibrosis (MF). Ruxolitinib has significant advantages in spleen reduction and increasing 5-year overall survival (OS), and ruxolitinib-based combinations might provide more benefits than ruxolitinib monotherapy. In this review,… read more here.
Keywords: myelofibrosis; based combinations; treatment related; ruxolitinib based ... See more keywords
CDC25c expression in patients with myelofibrosis is associated with stronger myeloproliferation and shorter overall survival
Sign Up to like & getrecommendations! Published in 2020 at "Wiener klinische Wochenschrift"
DOI: 10.1007/s00508-020-01738-2
Abstract: Cell division cycle 25c (CDC25c) is a gene coding a phosphatase controlling entry into mitosis upon activation through Polo-like kinase 1 (PLK1) and serves as a key regulator of cell division. The CDC25c was reported… read more here.
Keywords: cdc25c; cdc25c expression; myelofibrosis; expression ... See more keywords